Anixa Biosciences, Inc. (ANIX)
2.67
-0.11
(-3.96%)
USD |
NASDAQ |
Oct 16, 16:00
2.67
0.00 (0.00%)
After-Hours: 20:00
Anixa Biosciences Cash from Investing (Quarterly) : -0.245M for July 31, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | -0.245M |
| April 30, 2026 | 0.422M |
| January 31, 2026 | 1.228M |
| October 31, 2025 | 0.654M |
| July 31, 2025 | -0.833M |
| April 30, 2025 | 2.342M |
| January 31, 2025 | 2.703M |
| October 31, 2024 | 0.867M |
| July 31, 2024 | 2.724M |
| April 30, 2024 | 0.556M |
| January 31, 2024 | 0.129M |
| October 31, 2023 | -0.593M |
| July 31, 2023 | -0.98M |
| April 30, 2023 | -3.444M |
| January 31, 2023 | -0.585M |
| October 31, 2022 | -9.917M |
| July 31, 2022 | -2.911M |
| April 30, 2022 | 0.25M |
| January 31, 2022 | 1.85M |
| October 31, 2021 | 2.807M |
| July 31, 2021 | 0.9995M |
| April 30, 2021 | -8.399M |
| January 31, 2021 | 0.6754M |
| October 31, 2020 | 0.50M |
| July 31, 2020 | -0.52M |
| Date | Value |
|---|---|
| April 30, 2020 | 0.25M |
| January 31, 2020 | -0.5358M |
| October 31, 2019 | -0.25M |
| July 31, 2019 | 0.65M |
| April 30, 2019 | -1.176M |
| January 31, 2019 | 0.25M |
| October 31, 2018 | 0.7434M |
| July 31, 2018 | -1.52M |
| April 30, 2018 | 1.391M |
| January 31, 2018 | 0.8475M |
| October 31, 2017 | 0.7827M |
| July 31, 2017 | -2.004M |
| April 30, 2017 | -1.65M |
| January 31, 2017 | 0.1359M |
| October 31, 2016 | 1.148M |
| July 31, 2016 | 0.2465M |
| April 30, 2016 | -0.0351M |
| January 31, 2016 | 0.144M |
| October 31, 2015 | 0.00 |
| July 31, 2015 | 0.00 |
| April 30, 2015 | 0.25M |
| January 31, 2015 | -0.2048M |
| October 31, 2014 | 0.0471M |
| July 31, 2014 | -0.5025M |
| April 30, 2014 | 0.3987M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
| Sarepta Therapeutics, Inc. | -93.37M |
| Vicapsys Life Sciences, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.77M |
| Cash from Financing (Quarterly) | 1.936M |
| Free Cash Flow | -7.376M |
| Free Cash Flow Per Share (Quarterly) | -0.0518 |
| Free Cash Flow to Equity (Quarterly) | -1.76M |
| Free Cash Flow to Firm (Quarterly) | -1.77M |
| Free Cash Flow Yield | -8.24% |